Tumor necrosis family receptor superfamily member 9/tumor necrosis factor receptor-associated factor 1 pathway on hepatitis C viral persistence and natural history. 2020

Julia Peña-Asensio, and Eduardo Sanz-de-Villalobos, and Joaquín Miquel, and Juan Ramón Larrubia
Department of Systems Biology, Guadalajara University Hospital. University of Alcalá, Guadalajara E-19002, Guadalajara, Spain.

Hepatitis C virus (HCV) infection is an excellent immunological model for understanding the mechanisms developed by non-cytopathic viruses and tumors to evade the adaptative immune response. The antigen-specific cytotoxic T cell response is essential for keeping HCV under control, but during persistent infection, these cells become exhausted or even deleted. The exhaustion process is progressive and depends on the infection duration and level of antigenemia. During high antigenic load and long duration of infection, T cells become extremely exhausted and ultimately disappear due to apoptosis. The development of exhaustion involves the impairment of positive co-stimulation induced by regulatory cytokines, such as transforming growth factor beta 1. This cytokine downregulates tumor necrosis factor receptor (TNFR)-associated factor 1 (TRAF1), the signal transducer of the T cell co-stimulatory molecule TNFR superfamily member 9 (known as 4-1BB). This impairment correlates with the low reactivity of T cells and an exhaustion phenotype. Treatment with interleukin-7 in vitro restores TRAF1 expression and rescues T cell effector function. The process of TRAF1 loss and its in vitro recovery is hierarchical, and more affected by severe disease progression. In conclusion, TRAF1 dynamics on T cells define a new pathogenic model that describes some aspects of the natural history of HCV, and sheds light on novel immunotherapy strategies for chronic viral infections and cancer.

UI MeSH Term Description Entries

Related Publications

Julia Peña-Asensio, and Eduardo Sanz-de-Villalobos, and Joaquín Miquel, and Juan Ramón Larrubia
January 1995, Journal of inflammation,
Julia Peña-Asensio, and Eduardo Sanz-de-Villalobos, and Joaquín Miquel, and Juan Ramón Larrubia
January 2009, Advances in experimental medicine and biology,
Julia Peña-Asensio, and Eduardo Sanz-de-Villalobos, and Joaquín Miquel, and Juan Ramón Larrubia
May 2009, Immunological reviews,
Julia Peña-Asensio, and Eduardo Sanz-de-Villalobos, and Joaquín Miquel, and Juan Ramón Larrubia
November 2000, The Journal of biological chemistry,
Julia Peña-Asensio, and Eduardo Sanz-de-Villalobos, and Joaquín Miquel, and Juan Ramón Larrubia
November 1999, Genomics,
Julia Peña-Asensio, and Eduardo Sanz-de-Villalobos, and Joaquín Miquel, and Juan Ramón Larrubia
December 2003, La Revue de medecine interne,
Julia Peña-Asensio, and Eduardo Sanz-de-Villalobos, and Joaquín Miquel, and Juan Ramón Larrubia
September 2018, Scientific reports,
Julia Peña-Asensio, and Eduardo Sanz-de-Villalobos, and Joaquín Miquel, and Juan Ramón Larrubia
January 2002, Immunologic research,
Julia Peña-Asensio, and Eduardo Sanz-de-Villalobos, and Joaquín Miquel, and Juan Ramón Larrubia
June 2010, Annals of surgical oncology,
Julia Peña-Asensio, and Eduardo Sanz-de-Villalobos, and Joaquín Miquel, and Juan Ramón Larrubia
January 2006, Current directions in autoimmunity,
Copied contents to your clipboard!